Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms CONQUER
- Sponsors Eli Lilly and Company
- 03 May 2023 Results of post hoc analysis (n=3348) assessing at population and individual patient levels, the sustained response of reduction in migraine headache days in patients with migraine treated with galcanezumab from two 6-month episodic migraine (EM; EVOLVE-1/EVOLVE-2), one 3-month chronic migraine (CM; REGAIN), and one 3-month treatment-resistant migraine (CONQUER) studies, published in the Headache.
- 27 Apr 2023 Results of pooled analysis(n=1551 from 3 studies EVOLVE-1, EVOLVE-2, and CONQUER ) assessing Clinically meaningful improvement in disability (MIDAS score) in the absence of greater than 50% reductions in monthly migraine days with galcanezumab presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 16 Feb 2023 Results of post hoc analysis assessing changes in interictal burden with galcanezumab versus placebo in patients with episodic (EM) or chronic migraine published in the Headache